Pacific Edge Limited · NZX:PEB
Pacific Edge — Shareholder Meeting (August 2015)
41 slides from Pacific Edge's shareholder meeting presentation, Aug 13, 2015
Slide 1: Annual Meeting of Shareholders
Annual Mee)ng of Shareholders 13 August 2015
Slide 2: Chairman
CHAIRMAN Chris Swann Pacific Edge 2015 Annual Mee)ng
Slide 3: Board of Directors
BOARD OF DIRECTORS Experienced Board With A Range Of Complementary Skills Which Add Value To Pacific Edge Chris Swann Chairman GOVERNANCE Board of Directors David Band Independent Director Experience in governance, finance, cancer research, biotechnology and life sciences, Anatole Masfen Non-‐Execu)v
Slide 4: Management
MANAGEMENT Providing The Experience and Capability to Deliver on Pacific Edge’s Growth Strategy David Darling Chief Execu3ve Officer MANAGEMENT TEAM Jimmy SuWe Chief Opera)ng Officer Experienced and knowledgeable in the following areas: Parry Guilford Chief Scien)fic Officer Development and interna)onal com
Slide 5: Meeting Agenda
MEETING AGENDA • Presenta)ons: • Address from the Chair, Chris Swann • Address from the Chief Execu)ve Officer, David Darling • Shareholder Discussion • Resolu)ons as per No)ce of Mee)ng • Re-‐elec)on of Anatole Masfen as a director • Re-‐elec)on of Bryan Williams as a director • Authorise the direc
Slide 6: Our Strategy
OUR STRATEGY Growth Strategy, Primarily Focused On The USA Market OUR OFFER Delivering innova)ve solu)ons for the early detec)on and be^er management of cancer Current focus on building a suite of Cxbladder tests, to increase detec)on and be^er management of bladder cancer Our tests are non-‐invasi
Slide 7: Shareholder Compensation Update
SHAREHOLDER COMPENSATION UPDATE • In May 2015, Pacific Edge announced a se^lement with FMA in regards to what FMA considered to be breaches of con)nuous disclosure obliga)ons • Delay of the announcements in ques)on was not made with an intent to breach con)nuous disclosure but rather to meet the spec
Slide 8: Funding for Growth
FUNDING FOR GROWTH Our Goal Is To ARain $100 Million Of Gross Revenue By Our FiVh Full Year Of Trading Cash and cash equivalents $7.82 million as at 31 March 2015 Debt free with funding from capital and technology grants for new product development, commercialisa)on and USA rollout Successful capita
Slide 9: Chief Executive Officer
CHIEF EXECUTIVE OFFICER David Darling Pacific Edge 2015 Annual Mee)ng
Slide 10: FY15 Highlights
FY15 HIGHLIGHTS Primary Focus On ExecuYon Of USA Market Strategy Strong UpliD in Launch of Second Strong Commercial Con3nued Investment Commercial Revenue Product, Cxbladder Progress in USA into Growth Triage Reflects rollout of USA Launched in NZ in late Increasing awareness, People, Intellectual sa
Slide 11: Our Goals and Progress in FY15: Sales Presence
OUR GOALS AND PROGRESS IN FY15 Expand Our USA Sales Presence And Drive Global Revenue Laboratory Throughput • Sales team expanded from four to twelve sales specialists in the USA • Strong growth in New Zealand and Australia USA NZ/Aust • Con)nuing increase in laboratory throughput with 278% increase
Slide 12: Our Goals and Progress in FY15: User Programmes
OUR GOALS AND PROGRESS IN FY15 ConYnue To Rollout User Programmes Con3nue To Rollout User Programmes, Driving Adop3on In Our Key Markets, Par3cularly In The USA • Increase in number of User Programmes in NZ, Australia and the USA • Announced large scale User Programme for 2,000 pa)ents in partnershi
Slide 13: Our Goals and Progress in FY15: Payers and NPNs
OUR GOALS AND PROGRESS IN FY15 ConYnue To NegoYate Agreements With Payers And NPNs Con)nue To Nego)ate Agreements With • Signed agreement with Mul)plan. Pacific Edge Payers And Na)onal And Regional now has agreements with the four largest NPNs Provider Networks (NPNs) In The USA including FedMed, ACP
Slide 14: Our Goals and Progress in FY15: R&D and IP
OUR GOALS AND PROGRESS IN FY15 ConYnue To Invest Into R&D and ProtecYon of IP Con)nue To Invest Into Research And Investment into clinical performance Development of New Products And valida)on studies, research and peer Protec)on of Our Intellectual Property reviewed science papers • Comple)on of tw
Slide 15: Our Goals and Progress in FY15: Cxbladder Triage Launch
OUR GOALS AND PROGRESS IN FY15 Successfully Launch Second Cxbladder Product, Cxbladder Triage • Launch of Cxbladder Triage in New Zealand in December 2014 on plan and to schedule • Cxbladder Triage performance published in peer reviewed science paper in the pres)gious interna)onal medical journal, B
Slide 16: Our Goals and Progress in FY15: Build Presence
OUR GOALS AND PROGRESS IN FY15 Build Presence In Targeted Markets Ongoing focus on building presence in • Launch of e-‐commerce site in New Zealand, other targeted markets making Cxbladder test easily accessible by New Zealand urologists, physicians and pa)ents • Signed agreements with urologists s
Slide 17: Investing in People
INVESTING IN PEOPLE Our success is founded on the exper)se, • Refreshed Board of Directors with three experience and commitment of the clinical, new directors in past two years PLUS new management and sales professionals who director for US subsidiary Board work for Pacific Edge • Strengthened corpor
Slide 18: FY15 Summary Financial Performance
FY15 SUMMARY FINANCIAL PERFORMANCE Result Reflects Ongoing Investment into Growth Strategy Strong uplis in sales revenue FY15 FY14 reflec)ng growing trac)on in USA $NZ’000 $NZ’000 market and strong increase in Sales Revenue 1,900 145 commercial customer numbers Second year of funding from a $4.5 Grant
Slide 19: Our Goals for FY16 and Progress to Date
OUR GOALS FOR FY16 AND PROGRESS TO DATE Pacific Edge 2015 Annual Mee)ng
Slide 20: USA Healthcare Market
USA HEALTHCARE MARKET Primary focus on USA healthcare market TARGETING THE USA, ONE OF THE OTHER MARKETS WORLD’S LARGEST HEALTHCARE MARKETS Established commercial partnerships in New Primary focus for Pacific Edge in the short to medium Zealand and Australia term Con)nuing to inves)gate other market
Slide 21: USA Healthcare Market: Infrastructure
USA HEALTHCARE MARKET: INFRASTRUCTURE Build Infrastructure for Growth • Planned recruitment of addi)onal six sales Expand to 18 sales execu)ves covering 19 execu)ves targeted major metropolitan regions, and increase the number of User Programmes • Two recruited to date and expected to start in their
Slide 22: USA Healthcare Market: Customers
USA HEALTHCARE MARKET: CUSTOMERS Capture Transforma3onal Customers CENTRE FOR MEDICARE & MEDICAID Complete the VA and CMS processes to allow SERVICES (CMS) access to these pa)ent groups and ini)ate commercial rela)onship Progressing discussions Complete the Kaiser Permanente User VETERAN’S ADMINISTR
Slide 23: User Programmes: Continued Rollout
USER PROGRAMMES: CONTINUED ROLLOUT Enhance Awareness and Foster Strong KAISER PERMANENTE Adop3on User Programme underway for Cxbladder Triage. Con)nue to roll out User Programmes to Recruitment of pa)ents commenced in July 2015 targeted urologists and clinical groups, par)cularly in the USA • 2000 p
Slide 24: South East Asia: Market Entry
SOUTH EAST ASIA: MARKET ENTRY Grow Our Interna3onal Presence • Con)nuing inves)ga)on into market Finalise business case for entry into the opportuni)es market and look to establish opera)ons in Singapore • Two dis)nct markets segments of interest: o Pa)ents requiring tes)ng for bladder cancer o Medi
Slide 25: Deliver a One Stop Shop of Cxbladder Products
DELIVER A ONE STOP SHOP OF CXBLADDER PRODUCTS Our aim is to provide urologists with a ‘one stop shop’ by offering a suite of Cxbladder products designed to meet the specific clinical needs of the different pa)ent groups To be used by clinicians and physicians responsible for the primary Cxbladder Triag
Slide 26: Cxbladder Triage: USA Launch
CXBLADDER TRIAGE: USA LAUNCH Launch Cxbladder Triage in the USA • Launch programme for Cxbladder Triage in the USA underway early July 2015 with commercial go-‐live expected in October 2015 • Received CLIA approval for Dunedin laboratory in August 2015 • Expect to have CLIA approval for Hershey lab
Slide 27: Cxbladder Pipeline: Product Development
CXBLADDER PIPELINE: PRODUCT DEVELOPMENT Bring into commercialisa)on Cxbladder • Con)nuing development of third Cxbladder Monitor and Predict, with ini)al launch product – Cxbladder Monitor in New Zealand and a fast follow up in the USA • On track for launch in late-‐2015 in New Zealand • Con)nuing
Slide 28: Engagement: Patient Community
ENGAGEMENT: PATIENT COMMUNITY Engage With The People Who MaZer Pacific Edge is the leading sponsor of Launch online pa)ent community for bladder bladdercancer.me, developed and cancer pa)ents and their families empowered by Melon Health Pacific Edge 2015 Annual Mee)ng
Slide 29: Bladdercancer.me
Bladdercancer.me • Provides online, relevant resources for bladder cancer pa)ents • Peer support • Access to appropriate healthcare providers • Symptom tracking Referral site to enable pa)ents to seek the most appropriate healthcare providers and solu)ons Pacific Edge 2015 Annual Mee)ng
Slide 30: Looking Forward
LOOKING FOWARD Pacific Edge 2015 Annual Mee)ng
Slide 31: Strategic Opportunities for Growth
STRATEGIC OPPORTUNITIES FOR GROWTH Targe)ng High Growth Over The Medium Term by Crea)ng More Products and Building Sales in an Increasing Number of Markets • Development of suite of Cxbladder products More Products • IP over other cancer expressions with opportunity to develop specific diagnos)c test
Slide 32: An Exciting Future for Our Company
AN EXCITING FUTURE FOR OUR COMPANY We are excited about the opportuni1es ahead of us and expect our laboratory through-‐put and commercial revenue to con1nue growing strongly as we add more exci1ng Cxbladder products and as more clinicians and pa1ents use our innova1ve cancer diagnos1c products. Pa
Slide 33: Shareholder Discussion
SHAREHOLDER DISCUSSION Pacific Edge 2015 Annual Mee)ng
Slide 34: Resolution: Re-election of Anatole Masfen
RESOLUTION: Re-‐elecYon of Anatole Masfen That Anatole Masfen, who re)res by rota)on and is eligible for re-‐elec)on, be re-‐elected as a Director of the Company Pacific Edge 2015 Annual Mee)ng
Slide 35: Resolution: Re-election of Bryan Williams
RESOLUTION: Re-‐elecYon of Bryan Williams That Bryan Williams, who re)res by rota)on and is eligible for re-‐elec)on, be re-‐elected as a Director of the Company Pacific Edge 2015 Annual Mee)ng
Slide 36: Resolution: Auditor's Remuneration
RESOLUTION: Auditor’s RemuneraYon That the Directors of the Company be authorised to fix the auditor's remunera)on for the ensuing year Pacific Edge 2015 Annual Mee)ng
Slide 37: Proxies
PROXIES We have received the following valid votes and proxies: PROXIES AND POSTAL VOTES FOR AGAINST DISCRETIONARY VALID VOTES/ % OF TOTAL PROXIES ISSUED RECEIVED CAPITAL Re-‐elec)on of Anatole 98.75% 0.53% 0.72% 141,106,519 37.47% Masfen (Resolu)on 1) Re-‐elec)on of Bryan 99.26% 0.02% 0.72% 141,0
Slide 38: Other Business
OTHER BUSINESS Pacific Edge 2015 Annual Mee)ng
Slide 39: Close of the Meeting
CLOSE OF THE MEETING PresentaYons are available at www.pacificedgedx.com Pacific Edge 2015 Annual Mee)ng
Slide 40: Contact details
www.pacificedge.co.nz www.cxbladder.com www.pacificedgedx.com David Darling Chief Execu)ve Officer Pacific Edge Limited Tel: +64 3 479 5802 Mobile: +64 21 797981 Email: dave.darling@pelnz.com Pacific Edge 2015 Annual Mee)ng
Slide 41: Disclaimer
DISCLAIMER Informa3on The informa)on in this presenta)on is an overview and does not contain all informa)on necessary to make an investment decision. It is intended to cons)tute a summary of certain informa)on rela)ng to the performance of Pacific Edge Limited . The informa)on in this presenta)on is